BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: CVE:RX
- CUSIP: N/A
- Web: N/A
- Market Cap: C$115.22 million
- Outstanding Shares: 14,403,000
- 52 Week Range: C$6.90 - C$9.12
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: N/A
- Annual Revenue: C$17.92 million
- Price / Sales: 6.43
- Book Value: C$1.16 per share
- Price / Book: 6.90
- Average Volume: 18,161 shs.
- Short Ratio: 0.1
Frequently Asked Questions for Biosyent (CVE:RX)
What is Biosyent's stock symbol?
Biosyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."
How were Biosyent's earnings last quarter?
Biosyent Inc. (CVE:RX) issued its quarterly earnings results on Thursday, May, 25th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by $0.02. The company had revenue of $3.82 million for the quarter, compared to the consensus estimate of $4.80 million. View Biosyent's Earnings History.
Who are some of Biosyent's key competitors?
Some companies that are related to Biosyent include WesternZagros Resources (WZR), Input Capital Corp (INP), Sterling Resources Ltd (SLG), Strategic Oil & Gas Ltd (SOG), NYX Gaming Group Ltd (NYX), BSM Technologies (GPS), Orezone Gold Corp (ORE), Pan Orient Energy Corp. (POE), Mosaic Capital Corp (M), Madalena Energy (MVN), Canamax Energy Ltd (CAC), Titanium Co. (TIC), Atico Mining Corp (ATY), Luna Gold Corp (LGC), Conifex Timber (CFF), Ikkuma Resources Corp (IKM), Africa Energy Corp (AFE) and Atacama Pacific Gold (ATM).
How do I buy Biosyent stock?
Shares of Biosyent and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
How much does a share of Biosyent stock cost?
One share of Biosyent stock can currently be purchased for approximately C$8.00.
Consensus Ratings for Biosyent (CVE:RX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Biosyent (CVE:RX)
(Data available from 5/27/2015 forward)
|2/13/2017||Bloom Burton||Reiterated Rating||Accumulate|
|8/14/2015||Cantor Fitzgerald||Lower Price Target||Speculative Buy||C$13.25 -> C$9.00|
Earnings History for Biosyent (CVE:RX)Earnings History by Quarter for Biosyent (CVE:RX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/25/2017||Q1 2017||$0.08||$0.06||$4.80 million||$3.82 million||View||N/A|
Earnings Estimates for Biosyent (CVE:RX)
2017 EPS Consensus Estimate: $0.34
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Biosyent (CVE:RX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Biosyent (CVE:RX)Insider Trades by Quarter for Biosyent (CVE:RX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/31/2017||Douglas Robert Larson||Director||Sell||900||C$7.75||C$6,975.00|
|9/8/2016||Douglas Robert Larson||Director||Sell||800||C$8.35||C$6,680.00|
Headline Trends for Biosyent (CVE:RX)
Latest Headlines for Biosyent (CVE:RX)
Biosyent (RX) Chart for Saturday, May, 27, 2017